The SCT is proud to announce that the first Galapagos Award for Drug Discovery Chemistry has been attributed to the interdisciplinary project from BioVersys (Dr Olivier Defert, candidate team representative), Université de Lille (Pr Nicolas Willand), Institut Pasteur de Lille/Inserm (Dr Alain Baulard), and GSK (Dr Modesto Remuinan). Starting from early academic and Biotech research their work culminated in the identification of a novel antituberculosis agent, BVL-GSK098, as a clinical candidate targeting a novel transcriptional regulator, called "VirS".
In line Galapagos’ mission to develop first-in-class medicines based on the discovery of novel targets we are happy to acknowledge the contribution of Olivier Defert’s team to the progress of modern medicinal chemistry and drug discovery innovation.The SCT thanks Galapagos for this partnership to acknowledge excellence in interdisciplinary medicinal chemistry for the benefit of patients. The award will be presented at the EFMC-ISMC in Nice.